<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28423123</article-id><article-id pub-id-type="pmc">5382906</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2016-0028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>N-acetylcysteine <italic>versus</italic> Dopamine to Prevent Acute
Kidney Injury after Cardiac Surgery in Patients with Preexisting Moderate Renal
Insufficiency</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Savluk</surname><given-names>Omer Faruk</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Guzelmeric</surname><given-names>Fusun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yavuz</surname><given-names>Yasemin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cevirme</surname><given-names>Deniz</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gurcu</surname><given-names>Emre</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ogus</surname><given-names>Halide</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Orki</surname><given-names>Tulay</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kocak</surname><given-names>Tuncer</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Kartal Kosuyolu High Training and Education Hospital, Istanbul,
Turkey.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Omer Faruk Savluk, Denizer Street - Kartal
- Istanbul, Turkey - Zip code: 34865. E-mail:
<email>dromersavluk@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2017</year></pub-date><volume>32</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><history><date date-type="received"><day>01</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>12</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Acute kidney injury after cardiac surgery is associated with mortality and
morbidity. Therefore, strategies to prevent acute kidney injury are very
important. The aim of this placebo-controlled randomized double-blind study
was to compare the prophylactic efficacy of N-Acetylcysteine and dopamine
administration in patients with pre-existing moderate renal insufficiency
who were undergoing cardiopulmonary bypass.</p></sec><sec><title>Methods</title><p>This study included 135 patients with pre-existing moderate renal
insufficiency who were scheduled for coronary artery bypass grafting
surgery. Serum creatinine and GFR were recorded preoperatively and on the
first and second postoperative days.</p></sec><sec><title>Results</title><p>On the first and second postoperative days, the drugs used showed
statistically significant differences among the creatinine groups
(<italic>P</italic>&#x0003c;0.001). According to Tukey&#x02019;s HSD, on the first
and second PO, the creatinine of Group N, D and P were significantly
different (<italic>P</italic>&#x0003c;0.001). On the first and second PO, the
used drugs showed statistically significant differences among the effects of
eGFR (<italic>P</italic>&#x0003c;0.001). According to Tukey&#x02019;s HSD on the first
postoperative day, the average eGFR score of Group N compared to D and P
were significantly difference (<italic>P</italic>&#x0003c;0.001). On the second
postoperative day, the eGFR of Group N and D showed no difference
(<italic>P</italic>=0.37), but P showed a difference
(<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Conclusion</title><p>We found that the prophylactic use of intravenous N-Acetylcysteine had a
protective effect on renal function, whereas the application of renal dose
dopamine did not have a protective effect in patients with pre-existing
moderate renal failure.</p></sec></abstract><kwd-group><kwd>Acute Kidney Injury/Prevention &#x00026; Control</kwd><kwd>Cardiac Surgical Procedures</kwd><kwd>Acetylcysteine</kwd><kwd>Dopamine</kwd></kwd-group></article-meta></front><body><table-wrap id="t9" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AKI<break/> CABG<break/> CPB<break/> CVP<break/>
ECG<break/> EF<break/> eGFR<break/> GFR<break/> MAP<break/> NAC<break/>
NGAL<break/> ROS</td><td align="left" rowspan="1" colspan="1">= Acute kidney injury&#x000a0;<break/> = Coronary artery bypass
graft&#x000a0;<break/> = Cardiopulmonary bypass&#x000a0;<break/> = Central venous
pressure&#x000a0;<break/> = Electrocardiogram&#x000a0;<break/> = Ejection
fraction&#x000a0;<break/> = Estimated glomerular filtration rate&#x000a0;<break/> =
Glomerular filtration rate&#x000a0;<break/> = Mean arterial pressure&#x000a0;<break/> =
N-acetylcysteine&#x000a0;<break/> = Neutrophil gelatinase associated
lipocalin&#x000a0;<break/> = Reactive oxygen species</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Acute kidney injury (AKI) after cardiac surgery is associated with mortality and
morbidity<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. In recent
years, patients undergoing cardiac surgery have been increasingly older, and they
have experienced co-morbidity more frequently. Therefore, strategies to prevent AKI
are extremely important. The pathophysiology of AKI in patients undergoing cardiac
surgery is multifactorial and includes hemodynamic factors that could lead to kidney
hypoperfusion, effects of nephrotoxic drugs and consequences of the systemic
inflammatory reaction induced by cardiopulmonary bypass (CPB). These factors may
contribute to renal ischemia and systemic hypoxic inflammation. During CPB,
nonpulsatile flow and renal perfusion are reduced by approximately 30%, while mean
arterial pressure decreases. While patients with normal renal function can tolerate
this without developing any clinical disorders, it can be a problem for patients
with preexisting renal dysfunction.</p><p>Several drugs have been used for renal protection during cardiac operations,
including dopamine, mannitol, diuretics, fenoldopam, enalaprilat, dexamethasone, and
diltiazem<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.
N-acetylcysteine (NAC) is an alternative therapy that may prevent perioperative
kidney injury. Due to its anti-inflammatory and antioxidant properties, NAC
attenuates several mechanisms of kidney injury during cardiac surgery, namely the
systemic inflammatory response, free radical injury and ischemia<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. The effects of dopamine include an
increase in renal blood flow via activation of dopaminergic receptors in the renal
vasculature<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>The aim of this placebo-controlled randomized double-blind study was to compare the
prophylactic effects of NAC and dopamine administration in patients with preexisting
mild renal insufficiency undergoing coronary bypass using CPB on renal function.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients Population and Study Design</title><p>The institutional local ethics committee approved the protocol and informed
consent was obtained from each patient. This study was designed as a
placebo-controlled randomized double-blind study. The study included 135
patients with preexisting moderate renal insufficiency who were scheduled for
elective coronary artery bypass grafting surgery (CABG) with CPB.</p><p>The inclusion criteria were as follows: 1) age &#x0003e; 18 years; 2) preexisting
moderate renal insufficiency [glomerular filtration rate (GFR) &#x0003c; 60], with
moderate renal insufficiency defined as an estimated glomerular filtration rate
(eGFR) (Cockcroft-Gault equation) &#x0003c; 60 ml/min; and 3) CABG surgery with
CPB.</p><p>The exclusion criteria were as follows: 1) severe preexisting renal
insufficiency; 2) multiorgan failure; 3) preoperative hemodynamic instability
(patients receiving intra-aortic balloon pump support and vasoactive therapy);
4) planned off-pump surgery; 5) planned deep hypothermic circulatory arrest; 6)
previous cardiac surgery; 7) previous operation under emergency conditions; 8)
severe heart failure [patients with ejection fraction (EF) &#x0003c; 35%]; 9)
diabetes mellitus; and 10) allergies to NAC.</p></sec><sec><title>Randomization</title><p>The patients were randomly divided into three groups, as follows: Group N, 45
patients receiving NAC; Group D, 45 patients receiving renal-dose dopamine (2.5
mcg/kg/min); and Group P, 45 patients comprising the control group. In Group N,
50 mg/kg of NAC was administered as a loading dose in 100 cc of 0.9% NaCl for 15
minutes, and then 20 mg/kg/h of NAC was provided as an infusion in 100 cc of
0.9% NaCl during the operation. In Group D, 2.5 mcg/kg/min of dopamine (renal
dose) was initiated after induction and given during the operation (400 mg
dopamine in 100 cc of 0.9% NaCl). Finally, in Group P, the control group, 100 cc
of 0.9% NaCl was administered after induction for 15 minutes as a placebo.</p><p>Randomization assignment of patients to Groups N, D, and P was performed with a
list of random numbers generated by a computer program&#x02019;s random function. The
list contained the natural numbers 1, 2, and 3. These numbers were allocated as
follows: 1, Group N; 2, Group D; and 3, Group P. The allocation into the
treatment or the placebo group and the preparation of the study drug were
performed by an individual who as unrelated to the study. Personnel, patients,
and the individual participating in the data collection and data analysis were
blinded to the treatment assignments.</p></sec><sec><title>Anesthesia Management</title><p>The patients were evaluated preoperatively 1 day before surgery.
Electrocardiogram (ECG), pulse oximetry, cannulation of the invasive arterial
pressure (20 gauge) from the left radial artery, and peripheral venous access
(18 gauge) from the right arm were inserted into the patient, who was taken to
the operating room on the day of the surgery. After induction of anesthesia and
intubation, an 8F central venous catheter was inserted from the right internal
jugular vein. Midazolam (0.05 mg/kg), propofol (2 mg/kg), fentanyl (5 mcg/kg),
and rocuronium (0.6 mg/kg) were used for the induction of anesthesia. Anesthesia
was maintained with a mixture of 2% sevoflurane, 60% oxygen, and 40% air. In
addition, 0.2 mg/kg of rocuronium, 0.02 mg/kg of midazolam, and 1 mcg/kg of
fentanyl were applied every 30 minutes. All patients were ventilated with
positive pressure. Ventilation parameters were set as a tidal volume of 10 ml/kg
and a respiratory rate of 10-12/min, which was assessed by arterial blood gases.
All patients received 500 ml ringer lactate before the induction of anesthesia.
Thereafter, IV ringer lactate solution was infused to keep the central venous
pressure (CVP) at 10-12 mmHg.</p></sec><sec><title>Cardiopulmonary Bypass Management</title><p>Before cannulation for CPB, 3 mg/kg of heparin was administered for all patients.
When the activated coagulation time was &#x0003e; 400/sec, it was passed to the pump.
Nonpulsatile CPB flow rates of 2-2.4 L/min/m<sup>2</sup> were applied, and the
mean arterial pressure (MAP) was kept at 50-60 mmHg. Hematocrit concentration
was maintained at 25-28%. Moreover, mild hypothermia (28-30&#x000b0;C) was reached
during CPB. Myocardial protection was achieved with intermittent antegrade. A
temperature of 37&#x000b0;C was achieved after surgery, and the patient was removed from
CPB. Following this, coagulation was provided with protamine; once hemodynamic
stabilization (MAP 70-90 mmHg) was achieved, patients were brought to the
intensive care unit.</p></sec><sec><title>Data</title><p>Demographic (age, sex, and weight) and perioperative data (operation time,
cross-clamp time, EF, urine volume, and total amount of hydration) were
recorded. In addition, the side effects of NAC (rash, wheezing, hemolysis, and
neutropenia) were monitored continuously.</p><p>Serum creatinine and GFR were recorded preoperatively and on the first and second
postoperative days. GFR was calculated using the Cockcroft-Gault formula
(eGFR=[140- age] *weight/72 *SCr [mg/dL]).</p></sec><sec><title>Statistical Evaluation</title><p>All data were analyzed using SPSS 16.0 software. All groups were evaluated by
one-way analysis of variance (ANOVA) with repeated measurements. A
<italic>P</italic>-value &#x0003c; 0.05 was considered statistically significant.
The categorical values were evaluated using a chi-square test, and
<italic>P</italic>-values &#x0003c; 0.05 were considered statistically
significant. Tukey&#x02019;s HSD of the <italic>post hoc</italic> test was performed for
comparison to determine the source of this difference between the groups.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Between March 2013 and March 2014, 135 patients with preexisting moderate renal
insufficiency were divided randomly into three groups and given NAC (n=46),
renal-dose dopamine (2.5 mcg/kg/min; n=45), or a placebo (n=44). After
randomization, at the discretion of the attending surgeon, five patients underwent
unplanned off-pump surgery (three patients in the Group N and two in Group D). Four
patients underwent unplanned circulatory arrest (two in Group N, one in Group D, and
one in Group P). Six patients underwent reoperation (one in Group N, two in Group D,
and three patients in Group P). Thus, the statistical analyses included 120
participants. The patients&#x02019; characteristic is presented in <xref ref-type="table" rid="t1">Table 1</xref> and operative variables are presented in <xref ref-type="table" rid="t2">Table 2</xref> for each group. No statistically
significant differences among Groups N, D, and P were identified with respect to the
demographic characteristics or operative variables (<italic>P</italic>&#x0003e;0.05).
Moreover, there were no differences in the total amount of fluids given, but urine
outputs exhibited statistically significant differences among Groups N, D, and P,
with Group D showing a significant increase.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group N</th><th align="center" rowspan="1" colspan="1">Group D</th><th align="center" rowspan="1" colspan="1">Group P</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">63&#x000b1;5.9</td><td align="center" rowspan="1" colspan="1">62&#x000b1;5.8</td><td align="center" rowspan="1" colspan="1">63&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">79.3&#x000b1;13</td><td align="center" rowspan="1" colspan="1">81&#x000b1;15</td><td align="center" rowspan="1" colspan="1">77&#x000b1;14</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (men)</td><td align="center" rowspan="1" colspan="1">24 (60%)</td><td align="center" rowspan="1" colspan="1">22 (55%)</td><td align="center" rowspan="1" colspan="1">19 (47.5%)</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">53&#x000b1;12</td><td align="center" rowspan="1" colspan="1">56&#x000b1;9</td><td align="center" rowspan="1" colspan="1">55&#x000b1;10</td><td align="center" rowspan="1" colspan="1">0.83</td></tr></tbody></table></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Intraoperative variables.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group N</th><th align="center" rowspan="1" colspan="1">Group D</th><th align="center" rowspan="1" colspan="1">Group P</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Operation period (min)</td><td align="center" rowspan="1" colspan="1">253&#x000b1;42.1</td><td align="center" rowspan="1" colspan="1">255&#x000b1;39.7</td><td align="center" rowspan="1" colspan="1">254&#x000b1;40.5</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic cross clamp period (min)</td><td align="center" rowspan="1" colspan="1">46&#x000b1;17.3</td><td align="center" rowspan="1" colspan="1">48&#x000b1;15.5</td><td align="center" rowspan="1" colspan="1">49&#x000b1;14.3</td><td align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass (min)</td><td align="center" rowspan="1" colspan="1">73&#x000b1;23.2</td><td align="center" rowspan="1" colspan="1">76&#x000b1;33.2</td><td align="center" rowspan="1" colspan="1">74&#x000b1;28</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Urine output during operation (ml)</td><td align="center" rowspan="1" colspan="1">575.6&#x000b1;281</td><td align="center" rowspan="1" colspan="1">912.3&#x000b1;535</td><td align="center" rowspan="1" colspan="1">623.6&#x000b1;337</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total amount of hydration (ml)</td><td align="center" rowspan="1" colspan="1">1755&#x000b1;128</td><td align="center" rowspan="1" colspan="1">1823&#x000b1;193</td><td align="center" rowspan="1" colspan="1">1712&#x000b1;154</td><td align="center" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood transfusion (n)</td><td align="center" rowspan="1" colspan="1">12 (30%)</td><td align="center" rowspan="1" colspan="1">10 (25%)</td><td align="center" rowspan="1" colspan="1">10 (25%)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Central venous pressure (cmH<sub>2</sub>0)</td><td align="center" rowspan="1" colspan="1">7.49&#x000b1;1.56</td><td align="center" rowspan="1" colspan="1">8.39&#x000b1;2.15</td><td align="center" rowspan="1" colspan="1">7.58&#x000b1;2.37</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean arterial pressure (mmHg)<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1">58.15&#x000b1;5.24</td><td align="center" rowspan="1" colspan="1">59.83&#x000b1;7.73</td><td align="center" rowspan="1" colspan="1">57.35&#x000b1;6.61</td><td align="center" rowspan="1" colspan="1">0.21</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Lowest value on bypass</p></fn></table-wrap-foot></table-wrap><p>None of the patients presented side effects of NAC (rash, wheezing, superficial
phlebitis, hemolysis, or neutropenia). In addition, no patients required dialysis in
the postoperative period.</p><p>Preoperative eGFR showed no statistically significant differences among Groups N, D,
and P (<italic>P</italic>=0.43). In the first and second postoperative periods, the
used drugs showed statistically significant differences in terms of the effects of
eGFR (<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t3">Table 3</xref>).
A <italic>post hoc</italic> test was performed for comparison to determine the
source of this difference between the groups. According to Tukey&#x02019;s HSD multiple
comparison test results, in the first postoperative period, the average eGFR score
of Group N compared to Group D and Group P was significantly different
(<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t4">Table 4</xref>).
In the second postoperative period, the eGFR average scores of Group N and Group D
showed no difference (<italic>P</italic>=0.37), but Group P exhibited a difference
(<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t5">Table 5</xref>).
Evolution of eGFR in the three groups from the first day to the second postoperative
day is shown in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Evaluation of eGFR with ANOVA.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">eGFR</th><th align="center" rowspan="1" colspan="1">Group N</th><th align="center" rowspan="1" colspan="1">Group D</th><th align="center" rowspan="1" colspan="1">Group P</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative</td><td align="center" rowspan="1" colspan="1">52.2&#x000b1;1.54</td><td align="center" rowspan="1" colspan="1">53.9&#x000b1;1.28</td><td align="center" rowspan="1" colspan="1">53.7&#x000b1;1.11</td><td align="center" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 1</td><td align="center" rowspan="1" colspan="1">55.4&#x000b1;1.38</td><td align="center" rowspan="1" colspan="1">53.4&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">52.6&#x000b1;1.23</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 2</td><td align="center" rowspan="1" colspan="1">53.1&#x000b1;1.04</td><td align="center" rowspan="1" colspan="1">52.8&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">51.3&#x000b1;1.27</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p><italic>P</italic>*: Postoperative day 1 <italic>vs</italic>.
Postoperative day 2.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Postoperative day 1. <italic>Post-hoc</italic> evaluation of eGFR with Tukey
HSD.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Comparison by instructor</th><th align="center" rowspan="1" colspan="1">Estimated Mean Difference</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1">Tukey Adjusted %95CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NAC</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">1.4;2.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">2.17;3.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dopamine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">-2</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">-2.6;-1.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.17;1.4</td><td align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Control</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">-2.8</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">-3.4;-2.17</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-0.8</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">-1.4;-0.17</td><td align="center" rowspan="1" colspan="1">0.009</td></tr></tbody></table></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Postoperative day 2. <italic>Post-hoc</italic> evaluation of eGFR with Tukey
HSD.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Comparison by instructor</th><th align="center" rowspan="1" colspan="1">Estimated Mean Difference</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1">Tukey Adjusted %95CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NAC</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">-2.5;0.9</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">1.75</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">1.17;2.33</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dopamine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">-0.32</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">-0.9;0.25</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">1.42</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.85;2</td><td align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Control</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">-1.75</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">-2.33;-1.17</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-1.42</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">-2;-0.85</td><td align="center" rowspan="1" colspan="1">0.009</td></tr></tbody></table></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Evolution of eGFR from first postoperative day to second postoperative
day in NAC, Dopamine and Placebo Groups.</p></caption><graphic xlink:href="rbccv-32-01-0008-g01"/></fig>
</p><p>Preoperative creatinine exhibited no statistically significant differences among
Groups N, D, and P (<italic>P</italic>=0.57). In the first and second postoperative
days, the drugs used showed statistically significant differences in relation to the
creatinine levels (<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t6">Table 6</xref>). A <italic>post hoc</italic> test was performed for comparison
to determine the source of this difference between the groups. According to Tukey&#x02019;s
HSD multiple comparison test results for the first and second postoperative days,
the average creatinine score of Group N and the average creatinine scores of Group D
and Group P were significantly different (<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t7">Tables 7</xref> and <xref ref-type="table" rid="t8">8</xref>). Evolution of creatinine in the three groups from first day to second
postoperative day is shown in <xref ref-type="fig" rid="f2">Figure 2</xref>.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Evaluation of creatinine with ANOVA.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</th><th align="center" rowspan="1" colspan="1">Group N</th><th align="center" rowspan="1" colspan="1">Group D</th><th align="center" rowspan="1" colspan="1">Group P</th><th align="center" rowspan="1" colspan="1">*<italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative&#x000a0;&#x000a0;</td><td align="center" rowspan="1" colspan="1">1.11&#x000b1;0.05</td><td align="center" rowspan="1" colspan="1">1.10&#x000b1;0.06</td><td align="center" rowspan="1" colspan="1">1.09&#x000b1;0.06</td><td align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 1</td><td align="center" rowspan="1" colspan="1">0.68&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">1.17&#x000b1;0.18</td><td align="center" rowspan="1" colspan="1">1.15&#x000b1;0.14</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 2</td><td align="center" rowspan="1" colspan="1">0.87&#x000b1;0.15</td><td align="center" rowspan="1" colspan="1">1.21&#x000b1;0.13</td><td align="center" rowspan="1" colspan="1">1.22&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p><italic>P</italic>*: Postoperative day 1 <italic>vs</italic>.
Postoperative day 2.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Postoperative day 1. Post-hoc evaluation of creatinine with Tukey HSD.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Comparison by instructor</th><th align="center" rowspan="1" colspan="1">Estimated Mean Difference</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1">Tukey Adjusted %95CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NAC</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-0.49</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">-0.52;-0.46</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">-0.47</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">-0.50;-0.44</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dopamine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.46;0.52</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">-0.006;0.004</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Control</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.44;0.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">-0.05;0.007</td><td align="center" rowspan="1" colspan="1">0.18</td></tr></tbody></table></table-wrap><table-wrap id="t8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Postoperative day 2. Post-hoc evaluation of creatinine with Tukey HSD.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Comparison by instructor</th><th align="center" rowspan="1" colspan="1">Estimated Mean Difference</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1">Tukey Adjusted %95CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NAC</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-0.34</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">-0.35;-0.32</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">-0.33</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">-0.34;-0.31</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dopamine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">0.32;0.35</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Control</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">-0.09;0.02</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Control</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NAC</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">0.31;0.35</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">-0.007</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">-0.02;0.009</td><td align="center" rowspan="1" colspan="1">0.54</td></tr></tbody></table></table-wrap><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Evolution of creatinine from first postoperative day to second
postoperative day in NAC, Dopamine and Placebo Groups.</p></caption><graphic xlink:href="rbccv-32-01-0008-g02"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our randomized double-blind study demonstrated that in patients with preexisting mild
renal failure undergoing CABG surgery, intravenous NAC had a renoprotective effect,
whereas continued low-dose dopamine (renal dose) had no protective effect. NAC
caused a statistically significant increase in eGFR and a decrease in
creatinine.</p><p>Ischemia-reperfusion injury, oxidative stress, and systemic inflammation are factors
considered to play a significant role in the development of AKI after cardiac
surgery<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. NAC has the
potential to be useful in this setting because it reduces the production of
oxygen-free radicals<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> and
proinflammatory cytokines<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>;
moreover, it has been shown to reduce the degree of ischemic AKI in animal
studies<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. At the same
time, it has been illustrated that NAC can reduce the risk of contrast nephropathy
in humans<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>, while the
renoprotective effect of NAC on CPB remains controversial.</p><p>Fischer et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> showed that NAC
reduced serum creatinine compared with the control group in their study. Moreover,
Wijeysundera et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> found that
there was preservation of postoperative eGFR in patients with preexisting moderate
renal dysfunction undergoing cardiac surgery and a significant reduction in
mortality with NAC. In our study, we observed increased creatinine clearance and
augmented eGFR.</p><p>Although intravenous administration of NAC does not clearly prevent AKI in patients
with renal insufficiency undergoing cardiac surgery, Sisillo et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> demonstrated a reduction in the
incidence of the serum creatinine concentration. However, this reduction did not
reach statistical significance. Furthermore, Ayhan et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> found that two different regimens of NAC in CABG
had some beneficial effects in the early the period of the surgery, but failed to
demonstrate preventive effects in patients in the late phase. In our study, we
demonstrated preventive effects between 24 and 48 hours after surgery.</p><p>Santana-Santos et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> showed
that the incidence of kidney injury was reduced with NAC in CABG. They investigated
two independent markers of kidney injury, namely cystatin C and neutrophil
gelatinase associated lipocalin (NGAL). In our study, the criteria used to
characterize AKI were serum creatinine and the Cockcroft-Gault equation.</p><p>Adabag et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> found that NAC
was not significantly associated with serum creatinine levels, the incidence of AKI,
hemodialysis requirements, operative mortality, intensive care, or length of
hospital stay in patients undergoing cardiac surgery. These patients received oral
NAC 600 mg twice daily preoperatively, but the researchers administered NAC orally,
and such administration may reduce its effectiveness. Tossios et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. suggested that NAC application
should begin before anesthesia induction to yield maximal benefit of its reactive
oxygen species (ROS)-scavenging properties. Considering that the NAC is estimated to
have a short half-life, at 2.2 hours<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, in this study, 50 mg/kg of NAC was administered as the
loading dose in 100 cc of 0.9% NaCl for 15 minutes; following this 20 mg/kg/h of NAC
was given as an infusion in 100 cc of 0.9% NaCl during the operation.</p><p>Hyninen et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> demonstrated
that NAC does not decrease the amount of kidney injury occurring in patients with
normal preoperative renal function undergoing abdominal aortic surgery. In addition,
Sucu et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> found that
intravenous NAC decreased the pump-induced oxido-inflammatory response during CPB.
In aortic surgery, it may result in kidney injury, and this may have different
mechanisms, with the exception oxido-inflammatory damage.</p><p>Haase et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> concluded that a
high dose (300 mg/kg intravenously) of NAC was no more effective than a placebo in
attenuating CPB-related acute renal failure in high-risk cardiac surgery patients.
Theoretically, high-dose NAC may have been excessive, and paradoxically, it may have
diminished the level of radical oxygen species, thereby attenuating their
potentially positive role in the regulation of intracellular signaling<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>There has been no consensus on the identification of the most effective route and
dose of NAC administration associated with significant renal protection in patients
undergoing CABG. However, NAC is an inexpensive, relatively safe, well-tolerated,
and widely used drug.</p><p>Although whether the use of low-dose dopamine protects against acute renal failure is
controversial, renal-dose dopamine is still one of the most frequently used
prophylactic measures to prevent renal dysfunction in patients. Its potentially
advantageous effects include an increase in renal blood flow via activation of
dopaminergic receptors in the renal vasculature<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>In several controlled trials with dopamine, improvements in several renal function
parameters have been reported<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.
However, Lassnigg et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>
showed that infusion of dopamine was ineffective for renal protection. Similarly, in
our study, we demonstrated that dopamine was not effective for renal protection. At
the same time, low-dose dopamine was shown to reverse periods of oliguria after CPB
in an uncontrolled study<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. In
our study, urine output increased in Group D compared with Group N and Group P.</p><p>Limitations</p><p>This study had several limitations. The diagnosis of acute renal failure was
primarily based on an increase in serum creatinine, which may not accurately reflect
true changes in GFR<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Moreover,
eGFR is a surrogate outcome that does not accurately represent the true GFR in the
non-steady state of AKI<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>;
however, alternative options are limited. Newer urinary biomarkers, such as cystatin
C or NGAL, may be more sensitive for identifying kidney damage<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. At present, however, serum
creatinine is the cheapest and most broadly accepted marker of kidney
function<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p><p>If NAC reduces creatinine generation by protecting the creatinine kinase activity,
our study would not have been adequate to explore this effect. However, it has
recently been suggested that NAC may decrease serum creatinine concentration without
affecting renal function<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>We found that intravenous prophylactic use of NAC had a protective effect on renal
function. In contrast, the application of renal-dose dopamine did not have a
protective effect in patients with preexisting moderate renal failure.</p><table-wrap id="t10" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">OFS</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FG</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YY</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DC</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EG</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; Manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HO</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TO</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TK</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript redaction or
critical review of its content; final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Kartal Kosuyolu High Training and Education
Hospital, Istanbul, Turkey.</p></fn><fn fn-type="other"><p>This article was presented as oral presentation in 30<sup>th</sup> Annual
Congress of the European Association of Cardiothoracic Anaesthesiology.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakar</surname><given-names>CV</given-names></name><name><surname>Worley</surname><given-names>S</given-names></name><name><surname>Arrigain</surname><given-names>S</given-names></name><name><surname>Yared</surname><given-names>JP</given-names></name><name><surname>Paganini</surname><given-names>EP</given-names></name></person-group><article-title>Influence of renal dysfunction on mortality after cardiac surgery
modifying effect of preoperative renal function</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><issue>3</issue><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">15698452</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000fc;rker</surname><given-names>H</given-names></name><name><surname>D&#x000f6;nmez</surname><given-names>A</given-names></name><name><surname>Zeyneloglu</surname><given-names>P</given-names></name><name><surname>Sezgin</surname><given-names>A</given-names></name><name><surname>Ulu&#x000e7;am</surname><given-names>M</given-names></name></person-group><article-title>Effects of enalaprilat infusion on hemodynamics and renal
function in patients undergoing cardiac surgery</article-title><source>Anadolu Kardiyol Derg</source><year>2004</year><volume>4</volume><issue>4</issue><fpage>296</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">15590356</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>MH</given-names></name><name><surname>Okusa</surname><given-names>MD</given-names></name></person-group><article-title>Acute kidney injury associated with cardiac
surgery</article-title><source>Clin J Am Soc Nephrol</source><year>2006</year><volume>1</volume><issue>1</issue><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17699187</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>NK</given-names></name><name><surname>Adams</surname><given-names>DF</given-names></name><name><surname>Mendell</surname><given-names>P</given-names></name><name><surname>Abrams</surname><given-names>HL</given-names></name><name><surname>Merrill</surname><given-names>JP</given-names></name></person-group><article-title>Renal vascular responses to dopamine haemodynamic and
angiographic observations in normal man</article-title><source>Clin Sci Mol Med</source><year>1973</year><volume>45</volume><issue>6</issue><fpage>733</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">4760032</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>KE</given-names></name><name><surname>Chu</surname><given-names>MW</given-names></name><name><surname>Novick</surname><given-names>RJ</given-names></name><name><surname>Fox</surname><given-names>SA</given-names></name><name><surname>Gallo</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>CM</given-names></name></person-group><article-title>Perioperative N-acetylcysteine to prevent renal dysfunction in
high-risk patients undergoing CABG surgery a randomized controlled
trial</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>3</issue><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">16030279</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucu</surname><given-names>N</given-names></name><name><surname>Cinel</surname><given-names>I</given-names></name><name><surname>Unlu</surname><given-names>A</given-names></name><name><surname>Aytacoglu</surname><given-names>B</given-names></name><name><surname>Tamer</surname><given-names>L</given-names></name><name><surname>Kocak</surname><given-names>Z</given-names></name><etal/></person-group><article-title>N-acetylcysteine for preventing pump-induced oxidoinflammatory
response during cardiopulmonary bypass</article-title><source>Surg Today</source><year>2004</year><volume>34</volume><issue>3</issue><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">14999536</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Depierreux</surname><given-names>M</given-names></name><name><surname>Van Asbeck</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Effects of N-acetylcysteine in endotoxic shock</article-title><source>J Crit Care</source><year>1994</year><volume>9</volume><issue>4</issue><fpage>236</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">7889134</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Jing</surname><given-names>H</given-names></name></person-group><article-title>N-acetylcysteine to ameliorate acute renal injury in rat
cardiopulmonary bypass model</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>133</volume><issue>3</issue><fpage>696</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">17320567</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>AM</given-names></name><name><surname>Dwamena</surname><given-names>B</given-names></name><name><surname>Cronin</surname><given-names>P</given-names></name><name><surname>Bernstain</surname><given-names>SJ</given-names></name><name><surname>Carlos</surname><given-names>RC</given-names></name></person-group><article-title>Meta-analysis effectiveness of drugs for preventing
contrast-induced neuropathy</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><issue>4</issue><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">18283206</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>UM</given-names></name><name><surname>Tossios</surname><given-names>P</given-names></name><name><surname>Mehlhorn</surname><given-names>U</given-names></name></person-group><article-title>Renal protection by radical scavenging in cardiac surgery
patients</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><issue>8</issue><fpage>1161</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">16083524</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Chan</surname><given-names>CT</given-names></name></person-group><article-title>N-acetylcysteine for preventing acute kidney injury in cardiac
surgery patients with pre-existing moderate renal
insufficiency</article-title><source>Can J Anaesth</source><year>2007</year><volume>54</volume><issue>11</issue><fpage>872</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">17975231</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisillo</surname><given-names>E</given-names></name><name><surname>Ceriani</surname><given-names>R</given-names></name><name><surname>Bortone</surname><given-names>F</given-names></name><name><surname>Juliano</surname><given-names>G</given-names></name><name><surname>Salvi</surname><given-names>L</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><etal/></person-group><article-title>N-acetylcysteine for prevention of acute renal failure in
patients with chronic renal insufficiency undergoing cardiac surgery a
prospective, randomized, clinical trial</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><issue>1</issue><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">18090169</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayhan</surname><given-names>B</given-names></name><name><surname>Pamuk</surname><given-names>G</given-names></name><name><surname>Kantar</surname><given-names>B</given-names></name><name><surname>Kanbak</surname><given-names>M</given-names></name><name><surname>Celebioglu</surname><given-names>B</given-names></name><name><surname>Aypar</surname><given-names>U</given-names></name></person-group><article-title>Renal functional effects of using N-acetylcysteine in cardiac
surgery</article-title><source>Anesthesia J</source><year>2012</year><volume>20</volume><fpage>159</fpage><lpage>167</lpage></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santana-Santos</surname><given-names>E</given-names></name><name><surname>Gowdak</surname><given-names>LH</given-names></name><name><surname>Gaiotto</surname><given-names>FA</given-names></name><name><surname>Puig</surname><given-names>LB</given-names></name><name><surname>Hajjar</surname><given-names>LA</given-names></name><name><surname>Zeferino</surname><given-names>SP</given-names></name><etal/></person-group><article-title>High dose of N-acetycysteine prevents acute kidney injury in
chronic kidney disease patients undergoing myocardial
revascularization</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>97</volume><issue>5</issue><fpage>1617</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">24657033</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adabag</surname><given-names>AS</given-names></name><name><surname>Ishani</surname></name><name><surname>Bloomfield</surname><given-names>HE</given-names></name><name><surname>Ngo</surname><given-names>AK</given-names></name><name><surname>Wilt</surname><given-names>TJ</given-names></name></person-group><article-title>Efficacy of N-acetylcysteine in preventing renal injury after
heart surgery a systematic review of randomized trials</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>15</issue><fpage>1910</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">19282300</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tossios</surname><given-names>P</given-names></name><name><surname>Bloch</surname><given-names>W</given-names></name><name><surname>Huebner</surname><given-names>A</given-names></name><name><surname>Raji</surname><given-names>MR</given-names></name><name><surname>Dodos</surname><given-names>F</given-names></name><name><surname>Klass</surname><given-names>O</given-names></name><etal/></person-group><article-title>N-acetylcysteine prevents reactive oxygen species-mediated
myocardial stress in patients undergoing cardiac surgery result of a
randomized, double-blind, placebo-controlled clinical trial</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>126</volume><issue>5</issue><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">14666027</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgstr&#x000f6;m</surname><given-names>L</given-names></name><name><surname>Kagedal</surname><given-names>B</given-names></name><name><surname>Paulsen</surname><given-names>O</given-names></name></person-group><article-title>Pharmacokinetics of N-acetylcysteine in man</article-title><source>Eur J Clin Pharmacol</source><year>1986</year><volume>31</volume><issue>2</issue><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">3803419</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyninen</surname><given-names>MS</given-names></name><name><surname>Niemi</surname><given-names>TT</given-names></name><name><surname>P&#x000f6;yhi&#x000e4;</surname><given-names>R</given-names></name><name><surname>Raininko</surname><given-names>EI</given-names></name><name><surname>Salmenper&#x000e4;</surname><given-names>MT</given-names></name><name><surname>Lep&#x000e4;ntalo</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>N-acetylcysteine for the prevention of kidney injury in abdominal
aortic surgery a randomized, double-blind, placebo-controlled
trial</article-title><source>Anesth Analg</source><year>2006</year><volume>102</volume><issue>6</issue><fpage>1638</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">16717300</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>M</given-names></name><name><surname>Haase-Fielitz</surname><given-names>A</given-names></name><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Reade</surname><given-names>MC</given-names></name><name><surname>Morgera</surname><given-names>S</given-names></name><name><surname>Seevenayagam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase II, randomized, controlled trial of high-dose
N-acetylcysteine in high-risk cardiac surgery patients</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>5</issue><fpage>1324</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">17414730</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magder</surname><given-names>S</given-names></name></person-group><article-title>Reactive oxygen species toxic molecules or spark of
life?</article-title><source>Crit Care</source><year>2006</year><volume>10</volume><issue>1</issue><fpage>208</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">16469133</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenberg</surname><given-names>K</given-names></name><name><surname>Smit</surname><given-names>AJ</given-names></name><name><surname>Girbes</surname><given-names>AR</given-names></name></person-group><article-title>Effects of low-dose dopamine on renal and systemic hemodynamics
during incremental norepinephrine infusion in healthy
volunteers</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><issue>2</issue><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">9468162</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassnigg</surname><given-names>A</given-names></name><name><surname>Donner</surname><given-names>E</given-names></name><name><surname>Grubhofer</surname><given-names>G</given-names></name><name><surname>Presterl</surname><given-names>E</given-names></name><name><surname>Druml</surname><given-names>W</given-names></name><name><surname>Hiesmayr</surname><given-names>M</given-names></name></person-group><article-title>Lack of renoprotective effects of dopamine and furosemide during
cardiac surgery</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><issue>1</issue><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">10616845</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>RF</given-names></name><name><surname>Lappas</surname><given-names>DG</given-names></name><name><surname>Kirklin</surname><given-names>JK</given-names></name><name><surname>Buckley</surname><given-names>MJ</given-names></name><name><surname>Lowenstein</surname><given-names>E</given-names></name></person-group><article-title>Acute oliguria after cardiopulmonary bypass renal functional
improvement with low-dose dopamine infusion</article-title><source>Crit Care Med</source><year>1982</year><volume>10</volume><issue>12</issue><fpage>852</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">7140333</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>MJ</given-names></name></person-group><article-title>N-acetylcysteine as a preventive measure for acute renal failure
a plea for more accurate detection of renal function in critically ill
patients</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>6</issue><fpage>1633</fpage><lpage>1634</lpage></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name></person-group><article-title>Defining acute renal failure physiological
principles</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>1</issue><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14618231</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Early diagnosis of acute kidney injury</article-title><source>Curr Opin Crit Care</source><year>2007</year><volume>13</volume><issue>6</issue><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">17975383</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Palevsky</surname><given-names>P</given-names></name><collab>Acute Dialysis Quality initiative workgroup</collab></person-group><article-title>Acute renal failure-definition, outcome measures, animal models,
fluid therapy and information technology needs the Second International
Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
Group</article-title><source>Critical Care</source><year>2004</year><volume>8</volume><issue>4</issue><fpage>R204</fpage><lpage>R212</lpage><pub-id pub-id-type="pmid">15312219</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Fischereder</surname><given-names>M</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>B</given-names></name><name><surname>Drobnik</surname><given-names>W</given-names></name><name><surname>Kr&#x000e4;mer</surname><given-names>BK</given-names></name></person-group><article-title>The value of N-acetylcysteine in the prevention of radiocontrast
agent-induced nephropathy seems questionable</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>2</issue><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">14747387</pub-id></element-citation></ref></ref-list></back></article>